Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Epigenetic Achilles’ heel of AML

Nature Cancer volume 2, pages 481–483 (2021)Cite this article

Subjects

Mutations in genes encoding epigenetic modifiers are frequent in acute myelogenous leukemia (AML) and have been proposed to cause AML via activation of oncogenes and repression of tumor suppressors. Two studies now identify unexpected oncogenic mechanisms and therapeutic vulnerabilities in AML arising from mutations in genes encoding the epigenetic regulators DNMT3A and ASXL1.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Novel oncogenic mechanisms of mutant epigenetic modifiers.

References

  1. The Cancer Genome Atlas Research Network. N. Engl. J. Med. 368, 2059–2074 (2013).

    Article  Google Scholar 

  2. Shlush, L. I. et al. Nature 506, 328–333 (2014).

    Article  CAS  Google Scholar 

  3. Ueda, K. et al. Cancer Cell 39, 529–547 (2021).

    Article  CAS  Google Scholar 

  4. Park, S. J. & Bejar, R. Exp. Hematol. 83, 105–112 (2020).

    Article  CAS  Google Scholar 

  5. Scheller, M. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00213-9 (2021).

  6. Wang, L. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00199-4 (2021).

  7. Chaudry, S. F. & Chevassut, T. J. BioMed Res. Int. 2017, 5473197 (2017).

    Article  Google Scholar 

  8. Russler-Germain, D. A. et al. Cancer Cell 25, 442–454 (2014).

    Article  CAS  Google Scholar 

  9. Baylin, S. B. & Jones, P. A. Nat. Rev. Cancer 11, 726–734 (2011).

    Article  CAS  Google Scholar 

  10. Treppendahl, M. B., Kristensen, L. S. & Gronbaek, K. J. Clin. Invest. 124, 47–55 (2014).

    Article  CAS  Google Scholar 

  11. Muller-Tidow, C. et al. Leukemia 30, 555–561 (2016).

    Article  CAS  Google Scholar 

  12. Chiappinelli, K. B. et al. Cell 162, 974–986 (2015).

    Article  CAS  Google Scholar 

  13. Roulois, D. et al. Cell 162, 961–973 (2015).

    Article  CAS  Google Scholar 

  14. Wolff, F., Leisch, M., Greil, R., Risch, A. & Pleyer, L. Cell Commun. Signal. 15, 13 (2017).

    Article  Google Scholar 

  15. Asada, S., Fujino, T., Goyama, S. & Kitamura, T. Cell. Mol. Life Sci. 76, 2511–2523 (2019).

    Article  CAS  Google Scholar 

  16. Abdel-Wahab, O. et al. Cancer Cell 22, 180–193 (2012).

    Article  CAS  Google Scholar 

  17. Pietras, E. M. Blood 130, 1693–1698 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA

    Koki Ueda & Ulrich Steidl

  2. Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan

    Koki Ueda

  3. Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

    Ulrich Steidl

  4. Department of Medicine (Oncology), Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY, USA

    Ulrich Steidl

  5. Blood Cancer Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Ulrich Steidl

Authors
  1. Koki Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Steidl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Steidl.

Ethics declarations

Competing interests

U.S. reports research support and personal fees from Bayer Healthcare; personal fees from Celgene; research support from GlaxoSmithKline; research support and personal fees from Aileron Therapeutics; personal fees and involvement as scientific cofounder and member on the board of directors of Stelexis Therapeutics; personal fees from Pieris Pharmaceuticals; personal fees from Novartis; and personal fees from Vor Biopharma outside the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ueda, K., Steidl, U. Epigenetic Achilles’ heel of AML. Nat Cancer 2, 481–483 (2021). https://doi.org/10.1038/s43018-021-00212-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00212-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer